8-K: AIM ImmunoTech Faces Delisting from NYSE American Due to Low Stock Price

AIM ImmunoTech has received notice from the NYSE American that it will be delisted due to the low selling price of its common stock.

Summary

• AIM ImmunoTech Inc. received a notice from NYSE Regulation on April 4, 2025, regarding the suspension of trading and commencement of delisting proceedings for its common stock from the NYSE American.
• The delisting is due to the Company no longer meeting the listing requirements under Section 1003(f)(v) of the NYSE American Company Guide, specifically related to the low selling price of its common stock.
• AIM ImmunoTech plans to appeal the delisting determination to the Exchanges Listing Qualifications Panel, but there is no guarantee of success.
• Trading of the Companys common stock is expected to commence on the Pink Open Market on April 7, 2025.
• The Company has issued a press release on April 4, 2025, discussing the delisting notice.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating financial difficulties and potential loss of investor confidence. The appeal offers a slight glimmer of hope, but the overall outlook is concerning.

Positives

• The Company intends to appeal the delisting decision.

Negatives

• AIM ImmunoTech is being delisted from the NYSE American due to its low stock price.
• There is no assurance that the appeal against the delisting will be successful.

Risks

• The Company faces the risk of being delisted from a major exchange, which could negatively impact investor confidence and stock liquidity.
• The appeal process may not be successful, leading to the delisting becoming permanent.
• Continued trading on the Pink Open Market may result in lower trading volumes and increased price volatility.

Future Outlook

The Company intends to regain compliance with the listing requirements of the NYSE American, but there is no guarantee of success.

Management Comments

• The Company plans to appeal the determination to the Exchanges Listing Qualifications Panel, although there can be no assurance that any such appeal will be successful.

Industry Context

Delisting from a major exchange can significantly impact a company's visibility and access to capital markets, potentially affecting its ability to fund research and development activities. Other companies in the immuno-pharma sector that have faced financial difficulties have also experienced similar challenges with maintaining exchange listings.

Comparison to Industry Standards

• Compared to companies like Sorrento Therapeutics, which faced similar delisting issues due to financial struggles, AIM ImmunoTech's situation highlights the vulnerability of smaller biotech firms to market volatility and funding challenges.
• Other companies such as Novavax have also experienced significant stock price fluctuations due to clinical trial results and regulatory delays, demonstrating the high-risk nature of the biotech industry.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment due to the delisting.
• Employees may face uncertainty regarding the Companys future prospects.
• The Companys ability to raise capital for research and development may be negatively impacted.

Next Steps

• AIM ImmunoTech will appeal the delisting determination to the Exchanges Listing Qualifications Panel.
• The Company's common stock is expected to begin trading on the Pink Open Market on April 7, 2025.

Key Dates

Keywords

delisting, NYSE American, AIM ImmunoTech, common stock, low selling price, appeal, Pink Open Market